Two of the major clinical aims in the management of patients with AIDS are prevention and treatment of opportunistic infections. Opportunistic strains of the Mycobacterium avium complex (MAC) pose some of the greatest difficulties in treatment of human immunodeficiency virus (HIV)-infected individuals, not only because of their multiple drug resistance but also because our understanding of their pathogenicity is limited (11) . It is clear that the major problem in the treatment of MAC infections is the resistance of these strains to various antimycobacterial agents (6, 12) . Unlike the genetically related multiple drug resistance that develops as the result of inadequate therapy for M. tuberculosis infection (21) , drug resistance in MAC is apparently associated with the cell envelope and its resistance to penetration by drugs (12, 13) . We have attempted to circumvent this problem in the past by using a combination of drugs chosen for their potential to inhibit the biosynthesis of components that contribute to the cell envelope structure, thus breaking the permeability barrier in MAC (16) . More recently, we showed that combined drug treatment with the macrolide clarithromycin, ethambutol (a cell envelope-inhibiting drug), and rifampin was highly bactericidal against both extracellular and intracellular MAC (18) .
We have recently shown that roxithromycin possesses significant in vitro activity against atypical mycobacteria (15) . Given the observations described above and keeping in mind the difficulty of treating MAC infections, we thought it desirable to test roxithromycin against MAC. As recent reports have indicated higher activity levels of macrolides at alkaline pH than at acidic pH (7, 14) , we also decided to determine the MICs of roxithromycin at both pH 6.8 and pH 7.4; 6.8 was taken as the standard pH used for drug screening in mycobacteria, whereas * Corresponding author. pH 7.4 was based on the physiological pH prevailing in the plasma. Further potentiation of the anti-MAC activity of roxithromycin by other antituberculous drugs (ethambutol, rifampin, amikacin, ofloxacin, and clofazimine) was also investigated radiometrically by the previously described x/y quotient method (18) (19) (20) .
The MAC strains used in this investigation (see Tables 1 and  2) were grown in complete 7H9 broth (supplemented with Middlebrook ADC enrichment; Difco Laboratories, Detroit, Mich.) containing 0.05% (vol/vol) Tween 80 to avoid clumping at 37°C and were harvested in their mid-logarithmic phase at an optical density of 0.15 (measured at 650 nm with a Coleman Junior II spectrophotometer), which corresponded to about 108 CFU/ml.
Radiometric determination of roxithromycin MICs was performed with a Bactec 460-TB apparatus (Becton Dickinson, Towson, Md.) as described earlier (14, (18) (19) (20) . The MICs were determined in parallel at pHs of 6.8 and 7.4. For the former pH, the medium used was commercially available Bactec 12B broth; in the latter case, the pH in the 12B vials was adjusted to 7.4 as previously described (14, 15 The radiometric x/y enhancement data were also confirmed by plating the bacterial suspensions from individual vials at the beginning and at the end of the experiment on 7H10 agar medium for viable-cell count enumeration, and the results were expressed as mean viable cell counts ± standard errors.
Roxithromycin and ofloxacin (Roussel-Uclaf), ethambutol (Lederle), amikacin (Bristol), and clofazimine (Ciba-Geigy) were kindly provided by their manufacturers, and rifampin was purchased from Sigma Chemical Co., St. Louis, Mo. The results obtained in the present investigation are summarized in Tables 1 and 2 and Fig. 1 Fig. 3 . A careful examination indicates a satisfactory correlation between the radiometric data in Fig. 1 and 2 , the corresponding xly quotients in Table 2 , and the viable-cell count data in Fig. 3 Fig. 4 . Thus, strain 551, against which roxithromycin-ethambutol-rifampin, roxithromycin-ethambutol-amikacin, and roxithromycin-ethambutol-ofloxacin had enhanced action ( Table 2 ; xly quotients of <0.001, <0.001, and 0.003, respectively), also had consistently flattened inhibition curves despite prolonged incubation periods of up to 8 days (Fig. 4A and B however, the strain grew exponentially thereafter (Fig. 4A) . Similar observations for strain 827 are illustrated in Fig. 4C and D.
We have previously shown that roxithromycin has significant in vitro activity against atypical mycobacteria, as radiometric MICs significantly below the reported peak levels of the drug in serum were found with such potential pathogens as MAC, M. scrofulaceum, M. szulgai, M. malmoense, M. xenopi, M. marinum, and M. kansasii, as well as rare pathogens such as M. chelonae and M. fortuitum (15) . Our present results further show that roxithromycin MICs for all of the MAC isolates tested (irrespective of the patient's HIV status) were below the reported maximum drug concentration in serum at the routine pH of 6.8 and that the MICs were further lowered by 1 to 2 dilutions at pH 7.4. Moreover, the anti-MAC activity of roxithromycin was enhanced for all 10 tested clinical isolates by ethambutol, for 3 isolates each by rifampin and clofazimine, for 2 isolates by amikacin, and for 1 isolate by ofloxacin. Screening of three-drug combinations (roxithromycin and Fig. 1 and 2 , respectively, at the beginning and at the end of the experiment. All of the drugs were used at sub-MIC levels. Rox, roxithromycin; Emb, ethambutol; Rif, rifampin; Amik, amikacin; Oflo, ofloxacin; Clofa, clofazimine; D, day.
ethambutol with a third potential anti-MAC drug, i.e., rifampin, amikacin, ofloxacin, or clofazimine) resulted in further enhancement of activity in 13 out of 20 drug combinations screened. Thus, in agreement with our previous results (18) (19) (20) , these observations confirm that ethambutol was able to break the drug exclusion barrier located in the MAC cell wall by inhibiting specific components of the barrier.
Since regimens for MAC infection in patients with AIDS and was exceedingly well tolerated (1, 3, 8) . Apart from ethambutol, both clofazimine (1, 8) and amikacin (2, 3), which we used in the present study, have been previously included in MAC treatment regimens and have yielded favorable results. This brief literature survey clearly indicates that apart from developing individual drugs for the treatment of MAC infections, one of the major issues today is the development of appropriate drug combination regimens.
Another major clinical aim in the management of patients with AIDS is the primary prevention of opportunistic infections. Recently, in an open, comparative, and randomized pilot study involving 52 HIV-infected patients with CD4 cell counts below 200/ml and no history of Pneumocystis carinii infections or cerebral toxoplasmosis, three chemoprophylactic regimens were compared. Eighteen patients received pentamidine alone (300 mg/month by aerosol), 17 received only roxithromycin (300 mg three times a week), and 17 received these doses of pentamidine and roxithromycin (5) . After a 16-to 18-month of follow-up, the numbers of episodes of P. carinii pneumonia and cerebral toxoplasmosis were significantly lower for patients treated with roxithromycin; furthermore, in contrast to the pentamidine group, none of the patients in the roxithromycin group developed mycobacterial infections.
Roxithromycin is characterized by high concentrations in serum resulting in a maximum concentration in serum of 10.8 jig/ml (time to peak, 1.5 h) after administration of a single 300-mg dose (15) and has been reported to concentrate more than 20-fold in a model of Staphylococcus aureus-infected macrophages (23) . By comparing projected intracellular concentrations of roxithromycin with its MIC for 90% of MAC strains (8 and 4 ,ug/ml at pH 6.8 and 7.4, respectively [ Table 1 ]), it can be concluded that this drug possesses a high level of anti-MAC activity as well as favorable pharmacokinetic properties, making it an immediate choice for future assessment in controlled clinical trials. On the basis of our results, it may be successfully combined with other potential anti-MAC drugs such as rifampin, clofazimine, amikacin, and fluoroquinolones, provided that ethambutol is maintained as an essential component in the therapeutic regimens to be tested.
In conclusion, roxithromycin possesses an antimycobacterial spectrum similar to that of clarithromycin (14, 18, 19) . It has been suggested that the efficacy of clarithromycin in eliminating MAC from the blood of patients with AIDS is associated with its high inhibitory activity at pH 7.4 (7) . Considering that intracellular accumulation of roxithromycin is higher under nonacidic conditions than under acidic conditions (23) and that, contrary to previous dogma, vesicles containing living, virulent MAC in experimentally infected human macrophages are indeed not acidic (4), we are currently evaluating the intracellular activity of roxithromycin used alone and in association with other antituberculous drugs in MAC-infected human macrophages.
